1737-21-9

Usage

InChI:InChI=1/C9H9FO3/c1-2-13-9(12)7-4-3-6(10)5-8(7)11/h3-5,11H,2H2,1H3

Upstream product

• 64-17-5 ethanol 
• 345-29-9 4-fluorosalicylic acid 
• 65-49-6 4-Aminosalicylic acid 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 94-08-6 4-methylbenzoic acid ethyl ester 
• 75-03-6 ethyl iodide 

Downstream Products

• 167758-90-9 4-fluoro-2-methoxybenzoic acid ethyl ester 
• 1071973-76-6 4-fluoro-2-methoxymethoxy-benzoic acid ethyl ester 
• 149556-92-3 ethyl 4-fluoro-2-hydroxy-5-iodobenzoate 
• 1643-78-3 4-fluoro-N,2-dihydroxybenzamide 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of N-hydroxy-aminobenzyloxyarylamide analogues as novel selective κ opioid receptor antagonists

Aminobenzyloxyarylamide derivatives 1a-i and 2a-t were designed and synthesized as novel selective κ opioid receptor (KOR) antagonists. The benzoyl amide moiety of LY2456302 was changed into N-hydroxybenzamide and benzisoxazole-3(2H)-one to investigate whether it could increase the binding affinity or selectivity for KOR. All target compounds were evaluated in radioligand binding assays for opioid receptor binding affinity. These efforts led to the identification of compound 1c (κ Ki = 179.9 nM), which exhibited high affinity for KOR. Moreover, the selectivity of KOR over MOR and DOR increased nearly 2-fold and 7-fold, respectively, compared with (±)LY2456302.

Boron-Containing Small Molecules as Anti-Inflammatory Agents

Compounds and methods of treating anti-inflammatory conditions are disclosed.

Ruthenium(II)-catalyzed synthesis of hydroxylated arenes with ester as an effective directing group

An unprecedented Ru(II) catalyzed ortho-hydroxylation has been developed for the facile synthesis of a variety of multifunctionalized arenes from easily accessible ethyl benzoates with ester as an efficient directing group. Both the TFA/TFAA cosolvent system and oxidants serve as the critical success factors in this transformation. The reaction demonstrates excellent reactivity, good functional group tolerance, and high yields.

(AZA)INDOLE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES

The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to (aza)indole derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro or cyano and the like; ring J represents aryl or heteroaryl and the like; Q represents carboxy or 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, nitro, alkyl, alkoxy and the like; X1, X2 and X3 independently represent CR2 or N; R1 and R2 independently represent halogen, cyano, haloalkyl, A-D-E-G, -N(-D-E-G)2 and the like, in the formula, A represents a single bond, O, S and the like; D and G independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E represents a single bond, O, S, COO, SO2 and the like.

Compounds containing an amino salicylic acid moiety linked to a sulphapyridine moiety via stable bridge

A compound of the formula Het--NR--SO2 --Ph2 --A--Ph1 (COOH)(OH) and tautomeric form, salts, solvates, C1-6 alkyl esters and pharmaceutical compositions of the compound. Ph1 and Ph2 are ben